ISSN: 1759-4774

Subscribe to this Journal

Journal Home

Journal Guideline

Nature Reviews Clinical Oncology Q1 Unclaimed

Nature Publishing Group United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Nature Reviews Clinical Oncology is a journal indexed in SJR in Oncology with an H index of 155. It has an SJR impact factor of 12,214 and it has a best quartile of Q1. It has an SJR impact factor of 12,214.

Nature Reviews Clinical Oncology focuses its scope in these topics and keywords: biomarkerdriven, discovery, trials, cancer, standard, clinical, biopsy, drug, hcc, gvhddacomitinib, ...

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Oncology (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

12,214

SJR Impact factor

155

H Index

144

Total Docs (Last Year)

587

Total Docs (3 years)

7574

Total Refs

8185

Total Cites (3 years)

277

Citable Docs (3 years)

13,76

Cites/Doc (2 years)

52,6

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

JAMA oncology Q1
Annals of Oncology Q1
Molecular Cancer Q1
CA - A Cancer Journal for Clinicians Q1
Cancer Discovery Q1

Compare this journals

Aims and Scope

Best articles by citations

Cetuximab's tip to become irresistible

New scoring system for melanoma accurately stratifies risk

G-CSF counteracts chemotherapy toxicity in neuroblastoma

Palliative primary tumour resection in mCRC - debate continues

FOLFIRI - improving toxicity in first-line treatment of advanced gastric cancer

FOLFOXIRI - improving outcomes of metastatic colorectal cancer

Erratum: Clinical trials of human papillomavirus vaccines and beyond

NK gene donor selection in AML

ALL: reducing cardiomyopathy

Is androgen-deprivation therapy chosen wisely?

CTCs - a predictive approach for targeted cancer therapy

Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery

SHOW MORE ARTICLES

Gazing at the crystal ball of European radiotherapy

Patients with brain metastases in early-phase trials

Can less really be more in melanoma?

Long-term response in high-risk CLL

Treatment of aggressive lymphomas with anti-CD19 CAR T cells

Is axillary lymph node clearance required in node-positive breast cancer?

CONKO conquers

PD-1 blockade: opening the door to attack

Improving cancer detection rates

Imatinib prior to allogeneic HSCT therapy improves both relapse and nonrelapse survival in patients with Ph+ALL

Locoregional versus systemic therapy - robust positive data remain elusive

BRAF and MEK inhibitors - good news comes in twos!